Navigation Links
AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
Date:8/12/2008

QUEBEC CITY, Aug. 12 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), a global biopharmaceutical company focused on endocrinology and oncology, announced today the appointment of Prof. Jurgen Engel, Ph.D. as its new President and CEO, effective as of September 1, 2008. Prof. Engel is currently Executive Vice President and Chief Scientific Officer of AEterna Zentaris. He succeeds Juergen Ernst, who had been acting as Interim President and CEO since April 2008. Mr. Ernst, current Chairman at AEterna Zentaris, will become Executive Chairman as of September 1, 2008.

"As a seasoned executive for many years at AEterna Zentaris, Prof. Engel has gained a deep knowledge of the Company's activities at all levels. We feel that his extensive expertise in drug development and commercialization as well as in strategic partnerships, make him the ideal person to lead the Company," said Mr. Ernst.

Prof. Engel added, "I am thrilled with this new challenge and will continue to dedicate all efforts to the successful development of our deep pipeline, especially the ongoing pivotal Phase 3 program in benign prostatic hyperplasia with our lead compound, cetrorelix."

Prof. Engel has been Chief Executive Officer of Zentaris AG since the beginning of 2001. Before joining AEterna Zentaris in December 2002, he was in charge of all R&D activities at ASTA Medica AG where he supervised more than 700 scientists and clinical professionals.

Prof. Engel holds a doctorate degree in organic chemistry from the Technical University of Braunschweig and an academic degree in pharmaceutical science from the University of Regensburg where he is an adjunct full professor at its School of Pharmacy. He is also Honorary Professor at
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris to Announce Second Quarter 2008 Financial and Operating Results on August 12, 2008
2. AEterna Zentaris Sells Quebec City Building for $7.1 million
3. AEterna Zentaris to Present at Upcoming Rodman & Renshaw Global Healthcare Conference and AUA Annual Meeting
4. AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal
5. AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results
6. AEterna Zentaris to Announce First Quarter 2008 Financial and Operating Results and Hold Annual Shareholder Meeting on May 7, 2008
7. AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan
8. AEterna Zentaris Partner, Spectrum, Provides Update on Ozarelix in Benign Prostatic Hyperplasia
9. AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia
10. AEterna Zentaris Announces Changes to its Management Team
11. AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... June 30, 2015  The Dr. Samadi Prostate Cancer Center ... offering a full suite of new genetic testing methods for ... for diagnosing prostate cancer. Dr. Samadi,s ... tests for assessing the risk and optimizing the diagnosis of ... very excited to now offer these revolutionary genetic tests to ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... company, launched “Cannavoices,” an unprecedented digital video and broadcast initiative. Produced by filmmakers, ... most dynamic collection of legal medical cannabis stories ever assembled. , Cannavoices ...
(Date:6/29/2015)... ... June 29, 2015 , ... ... Under the terms of the agreement, MediVet will acquire the rights to a ... MB-007 is currently in pre-clinical development as a potential next-generation treatment for various ...
(Date:6/29/2015)... June 29, 2015  AACC, a global scientific ... through laboratory medicine, is pleased to announce that ... Chemistry , has increased to 7.9 in the ... places Clinical Chemistry in the top ... significant influence of the research it publishes on ...
Breaking Biology Technology:New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 3New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 4New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 5Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 3MediVet Biologics Acquires Exclusive Patent License from Kansas State University 2MediVet Biologics Acquires Exclusive Patent License from Kansas State University 3AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 2AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 3
... , , , ... 20 The Molecular Genetics Core Facility (MGCF) at ... genetics researchers to conduct the highly economic targeted enrichment of ... will be receiving the Geniom RT Analyzer® from febit to ...
... , Washington , Jan. ... Alnylam announced today that the organizations are partnering to engage the ... and Alnylam Intellectual Property (IP) Pool.  The IP Pool was formed ... development of new medicines for the treatment of 16 neglected tropical ...
... ... (IPS), a leading, full-service engineering, construction, commissioning and qualification company dedicated to assisting ... Wareheim as Bioprocess Subject Matter Expert. , ... Lafayette Hill, PA (Vocus) January 20, 2010 ...
Cached Biology Technology:Molecular Genetics Core Facility at Children's Hospital Boston Selects HybSelect from febit for Targeted Resequencing 2Molecular Genetics Core Facility at Children's Hospital Boston Selects HybSelect from febit for Targeted Resequencing 3BIO Ventures for Global Health Chosen to Administer the GSK and Alnylam Intellectual Property Pool 2BIO Ventures for Global Health Chosen to Administer the GSK and Alnylam Intellectual Property Pool 3BIO Ventures for Global Health Chosen to Administer the GSK and Alnylam Intellectual Property Pool 4IPS Appoints Dave Wareheim as Bioprocess Subject Matter Expert 2IPS Appoints Dave Wareheim as Bioprocess Subject Matter Expert 3
(Date:6/23/2015)... Minn. , June 23, 2015   ... company that supports the entire spectrum of clinical ... iMedNet ™ , the company,s intuitive, ... been awarded a Silver 2015 Stevie® Award by ... Health Products & Services Website category.  The American ...
(Date:6/18/2015)... , June 18, 2015 This report analyzes ... by the following Product Segments, which includes Immunoassay Analyzers ... Immunoassay Systems, Radio Immunoassay Systems, and Nephelometric Immunoassay Systems. ... Canada , Japan ... , Latin America , and ...
(Date:6/17/2015)... June 17, 2015  Synaptics Inc. (NASDAQ: ... today announced that Xiaomi, one of the world,s ... ClearPad ® family of capacitive touchscreen ... circuits (DDICs) for its latest smartphones, the Xiaomi ... for full in-cell display solutions and DDICs in ...
Breaking Biology News(10 mins):MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3
... be the key to creating cyborg interfaces? Circuitry that links ... such as a robotic limb or artificial eye might one ... Writing in the International Journal of Medical Engineering ... "memristor" can be made using human blood. Memristors were a ...
... (Baltimore, MD) Today, the Interactive Autism Network (IAN), ... first major survey to study the experience of wandering ... disorders (ASD). The tendency of individuals with ASD to ... injury or even death, yet information on this critical ...
... State University has revealed a potential new way for plants ... and molecular biology professor, cites that this defense mechanism is ... plants and herbivores. Howe, in the current issue of ... offers insights to understanding the chemical weaponry of this war, ...
Cached Biology News:Blood simple circuitry for cyborgs 2Why do children with autism wander and bolt from safe places? 2The way to (kill) a bug's heart is through its stomach 2
Mouse monoclonal antibody raised against a partial recombinant ALPK3. NCBI Entrez Gene ID = ALPK3...
Mouse monoclonal antibody raised against a partial recombinant MYO7A. NCBI Entrez Gene ID = MYO7A...
... Cell Lines ,High Quality, Functionally-Validated, Ion Channel ... known for having a critical role in ... a key function in pain, CNS and ... have been investigated in therapeutic areas, such ...
Mouse monoclonal antibody raised against a partial recombinant ENTPD5. NCBI Entrez Gene ID = ENTPD5...
Biology Products: